11 Unstoppable Growth Stocks to Invest in Now

7. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Number of Hedge Fund Holders: 25

3-Year Revenue Growth: ~31.9%

% Increase on a YTD Basis: ~37.2%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology company focused on developing and commercializing novel oncology therapies. Robert Wasserman from Benchmark Co. maintained a “Buy” rating on the company’s stock with a price objective of $75.00. The analyst’s rating stems from factors such as the company’s impressive financial performance and strategic developments. In Q1 2025, Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s revenue came in at $264.9 million as compared to $195.9 million in Q1 2024. The 35% YoY growth was mainly aided by growth in royalty revenue and higher sales of bulk rHuPH20.

The analyst highlighted that Halozyme Therapeutics, Inc. (NASDAQ:HALO) has made significant progress in its development pipeline, receiving approvals for new indications as well as delivery mechanisms for numerous products. In April 2025, argenx received US FDA approval of VYVGART® Hytrulo prefilled syringe for self-injection for treating adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adult patients with CIDP. Furthermore, Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s strong operating cash flow and higher cash reserves, together with a new share repurchase program, aid the favourable outlook. Cash, cash equivalents, and marketable securities sat at $747.9 million on March 31, 2025 as compared to $596.1 million on December 31, 2024. This rise stemmed mainly from the cash generated from operations.